Compare Salesforce Inc (CRM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Salesforce Inc trades at $192.99 (market cap $161.73B), while Vertex Pharmaceuticals Incorporated trades at $526.83 (market cap $134.25B). The key difference: Salesforce Inc is the larger of the two by market cap, and Salesforce Inc pays a 0.89% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| CRM | VRTX | |
|---|---|---|
Market Cap | $161.73B | $134.25B |
Sector | Technology | Health |
52-Week High | $266.23 | $529.65 |
52-Week Low | $150.12 | $376.62 |
Enterprise Value | $191.77B | $128.37B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $192.33, down 2.62% amid broader software sector weakness driven by AI disruption concerns. The stock maintains strong fundamentals with consistent earnings beats, 77.64% gross margins, and 18.73% net income margin. Technical indicators show bullish momentum despite overbought RSI readings, with key support at $193. Analyst consensus remains strongly bullish with a $230.83 price target representing 20% upside potential.
CRM presents a compelling investment case with robust profitability, AI monetization growth, and discounted valuation. Near-term risks include software sector volatility and AI competition, but strong cash flow generation and institutional support provide stability. The current dip offers entry opportunity for long-term investors seeking exposure to enterprise software leadership.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
